Normal view MARC view ISBD view

Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.

MedStar author(s):

Citation: Journal of Heart & Lung Transplantation. 39(10):1050-1069, 2020 10.PMID: 32883559Institution: MedStar Washington Hospital CenterDepartment: PharmacyForm of publication: Journal ArticleMedline article type(s): EditorialSubject headings: *Consensus | *Drugs, Generic/pd [Pharmacology] | *Graft Rejection/pc [Prevention & Control] | *Immunosuppression/mt [Methods] | *Immunosuppressive Agents/pd [Pharmacology] | *Lung Transplantation | Drug Substitution | HumansYear: 2020 Local holdings: Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007ISSN:

1053-2498

Name of journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart TransplantationAbstract: In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. Copyright (c) 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.All authors: Baran D, Claridge T, Cochrane AB, Colvin M, Dawson K, Dipchand A, Doligalski C, Ensor CR, Flattery M, Ford K, Girgis R, Ivulich S, Jennings D, Khuu T, Kittleson M, Lindenfeld J, Lyster H, Miller T, Page RL 2nd, Peters L, Russell S, Scheel J, Schweiger M, Shullo M, Simpson K, Stuckey L, Tse T, Uber P, Weeks P, Weill D, Yost COriginally published: Journal of Heart & Lung Transplantation. 39(10):1050-1069, 2020 Oct.Fiscal year: FY2021Digital Object Identifier:

https://dx.doi.org/10.1016/j.healun.2020.06.024

Date added to catalog: 2020-10-06

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	32883559	Available		32883559

Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007

In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. Copyright (c) 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

English